Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $82 and keeps an Outperform rating on the shares. The firm adjusted its model following “highly compelling results” reported ...

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its ...

REDWOOD CITY, Calif., November 05, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.” ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...